Their investigation suggested L-selectin (CD62L) expressed on CD4+ T cells might help identify MS patients at high risk for PML, since all the eight patients who developed PML had a previous blood sample showing a level of CD62L expression below a hypothetical threshold [10]. Here, SELL is linked to myeloid sarcoma.